BACKGROUND: Our objective was to determine virological and clinical characteristics associated with virological failure in human immunodeficiency virus (HIV)-infected patients switching to darunavir/ritonavir (DRV/r) monotherapy. METHODS: The main outcome was virologic rebound, defined as 2 consecutive measurements of HIV-1 plasma RNA viral load (VL) >50 copies/mL. A logistic model was used to investigate which variables were predictive of a virologic rebound at weeks 48 (W48) and 96 (W96). RESULTS: Receiving DRV/r monotherapy was associated with virologic rebound at W48 (P = .016) and W96 (P = .002), comparable to triple therapy. In the DRV/r monotherapy group, at W48, having a VL >50 copies/mL at day 0 and even a baseline ultrasensitive VL >1 copy/mL were predictive factors to virologic rebound (P = .042 and P = .025, respectively). At W96, shorter time of prior antiretrovial therapy (ART) exposure (odds ratio [OR] = 2.93 per 5 years decrease; P = .006), higher HIV-1 DNA at day 0 (OR = 2.66 per 1 log(10) copies/10(6) cells increase; P = .04) and adherence <100% (OR = 3.84 vs 100%; P = .02) were associated with an increased risk of rebound. CONCLUSIONS: Factors associated with virological failure in patients receiving DRV/r monotherapy were having an initial blip, shorter time of antiretroviral treatment before monotherapy, and an adherence <100% during monotherapy. The importance of prior duration exposure to ART was in agreement with the impact of HIV-1 blood reservoir and VL level at baseline.
RCT Entities:
BACKGROUND: Our objective was to determine virological and clinical characteristics associated with virological failure in human immunodeficiency virus (HIV)-infectedpatients switching to darunavir/ritonavir (DRV/r) monotherapy. METHODS: The main outcome was virologic rebound, defined as 2 consecutive measurements of HIV-1 plasma RNA viral load (VL) >50 copies/mL. A logistic model was used to investigate which variables were predictive of a virologic rebound at weeks 48 (W48) and 96 (W96). RESULTS: Receiving DRV/r monotherapy was associated with virologic rebound at W48 (P = .016) and W96 (P = .002), comparable to triple therapy. In the DRV/r monotherapy group, at W48, having a VL >50 copies/mL at day 0 and even a baseline ultrasensitive VL >1 copy/mL were predictive factors to virologic rebound (P = .042 and P = .025, respectively). At W96, shorter time of prior antiretrovial therapy (ART) exposure (odds ratio [OR] = 2.93 per 5 years decrease; P = .006), higher HIV-1 DNA at day 0 (OR = 2.66 per 1 log(10) copies/10(6) cells increase; P = .04) and adherence <100% (OR = 3.84 vs 100%; P = .02) were associated with an increased risk of rebound. CONCLUSIONS: Factors associated with virological failure in patients receiving DRV/r monotherapy were having an initial blip, shorter time of antiretroviral treatment before monotherapy, and an adherence <100% during monotherapy. The importance of prior duration exposure to ART was in agreement with the impact of HIV-1 blood reservoir and VL level at baseline.
Authors: Babafemi O Taiwo; Vincent C Marconi; Baiba Berzins; Carlee B Moser; Amesika N Nyaku; Carl J Fichtenbaum; Constance A Benson; Timothy Wilkin; Susan L Koletar; Jonathan Colasanti; Edward P Acosta; Jonathan Z Li; Paul E Sax Journal: Clin Infect Dis Date: 2018-05-17 Impact factor: 9.079
Authors: A Calcagno; A Romito; C Atzori; V Ghisetti; C Cardellino; S Audagnotto; E Scarvaglieri; F Lipani; D Imperiale; G Di Perri; S Bonora Journal: J Neuroimmune Pharmacol Date: 2016-11-08 Impact factor: 4.147
Authors: José R Arribas; Manuela Doroana; Dan Turner; Linos Vandekerckhove; Adrian Streinu-Cercel Journal: AIDS Res Ther Date: 2013-01-24 Impact factor: 2.250
Authors: Sidonie Lambert-Niclot; Philippe Flandre; Marc-Antoine Valantin; Cathia Soulie; Slim Fourati; Marc Wirden; Sophie Sayon; Sophie Pakianather; Laurence Bocket; Bernard Masquelier; Georges Dos Santos; Christine Katlama; Vincent Calvez; Anne-Genevieve Marcelin Journal: PLoS One Date: 2012-07-25 Impact factor: 3.240